Antibodies, manufactured where the disease lives.
Salvitus engineers E. coli Nissle 1917 — a century-old probiotic — into an oral live biotherapeutic host that colonizes the colon and produces targeted dimeric IgA antibodies on site. One platform, two clinical programs: KRAS+ colorectal cancer and ulcerative colitis.
One engineered host, two therapeutic ladders
Every Salvitus therapy is built on the same chassis: engineered E. coli Nissle 1917, dosed as a once-daily oral capsule. The host colonizes the colon, and an added payload — or none at all — determines which disease it's built to address.
The Salvitus host colonizes the colon and delivers epitopes directly into the colonic lumen, inducing a targeted mucosal antibody response with intracellular reach — without genotoxic effects, and with the probiotic benefits Nissle 1917 has carried since 1917.
The engineered chassis removes the one liability of wild-type Nissle: colibactin production. It has been modified so it no longer produces colibactin, while every antibacterial and barrier-repair benefit is preserved.
Competitive exclusion of pathogens
Iron-scavenging siderophore-microcins starve and outcompete pathogenic bacteria in the gut.
Epithelial barrier reinforcement
Triggers ZO-2 and PKCζ redistribution at tight junctions, strengthening the gut lining against leakage and injury.
Immune & inflammatory modulation
Engages dendritic cells and shifts cytokine signaling toward an anti-inflammatory, tolerogenic gut environment.
A century of clinical validation
Sold since 1917 as Mutaflor; the wild-type chassis is an ECCO guideline-recognized therapy in its own right.
| Property | Wild-type Nissle 1917 | Engineered EcN (colibactin-negative) |
|---|---|---|
| Colibactin production | Active — pks island intact | Eliminated |
| Genotoxicity to host cells | DNA cross-links & double-strand breaks | None detected |
| Antibacterial activity | Fully active | Fully active — unchanged |
| Barrier & anti-inflammatory benefit | Present | Present — unchanged |
| Fit for chronic daily dosing | Genotoxicity is a liability | De-risked chassis |
SALV-0251 · KRAS+ Colorectal Cancer
KRAS-driven colorectal cancer remains among the hardest to treat
KRAS+ CRC carries a poorer prognosis than non-mutated tumors, and the therapies available today each run into the same wall: they can't selectively reach an intracellular target inside colonic epithelial cells without systemic cost.
From annual incidence to peak revenue opportunity
Multi-function oral neo-adjuvant therapy
Multiple integrated therapeutic pathways in one oral dose — active before and after surgery.
Seeks cancer cells & delivers immune education
Bacteria preferentially seek cancer cells and release training particles directing the immune system to produce targeted IgA against KRAS+ (ON) proteins.
Targeted dimeric IgA removes KRAS+
Upregulated pIgR escorts antibodies through epithelial membranes — binding and removing KRAS+ oncoproteins from the cell.
Drives pIgR upregulation → enhances chemo
Upregulated pIgR expression synergistically enhances chemotherapy performance and supports intracellular antibody transport.
Supports intestinal healing post-resection
SALV-0251 strengthens the intestinal barrier and promotes epithelial repair following surgical resection.
Orthotopic CT26 murine model
SALV-0251 with chemotherapy outperforms all other groups and virtually eliminates tumors, tracked by photon flux (tumor burden) through 30 days post-tumor administration.
Photon Flux Through 30 Days Post-Tumor
Key finding
Combination arms (Groups 5 & 6) show complete or near-complete tumor suppression by day 30 — dwarfing the strong, near-identical efficacy of chemo alone and pre-tumor SALV-0251 alone.
Extended timeline
Observation of Groups 5 & 6 was extended with a SALV-0251 booster on days 47–49, yielding continued suppression in both arms.
Next steps
Re-run with adjusted boosting and maintenance dosing across all SALV-0251 arms to further define the induced immune response.
Extended Timeline — Groups 5 & 6, Through Day 64
Key finding
The booster reversed the Group 5 trend, reducing an already-small tumor burden. Group 6 was further reduced, with 3 mice showing no measurable photon flux by day 64.
Next steps
A new trial extends the target window to 49 days and adds boosting & maintenance dosing to the SALV-0251 monotherapy arms.
From completed preclinical work to Phase II
Key milestones for the GMO LBP oncology asset, present stage through Phase I/II completion.
Engineered EcN Platform · Ulcerative Colitis
The Salvitus therapeutic ladder
One oral chassis, an added payload as disease severity increases — patients step up without switching drug classes or delivery formats.
Engineered EcN with JAK1 Epithelial Intracellular Therapy
Adds on-site dimeric IgA production that selectively binds JAK1 intracellularly in the colonic epithelium — no systemic exposure. Positioned against biologics and JAK1 inhibitors (e.g. Rinvoq) as the advanced-therapy line.
Engineered Nissle Only
Barrier repair, immune modulation, and competitive exclusion — the base probiotic mechanism, with genotoxicity engineered out. Positioned as a once-daily, non-5-ASA successor to mesalamine.
The UC drug market by disease severity
$8–9.5B in 2025, growing toward $15B+ by 2035 — Salvitus is positioned across the full spectrum. Figures are directional estimates synthesized from public market-research trackers; severity-tier splits vary by analyst.
A credible mesalamine successor
Three independent randomized trials, one consistent result: statistical equivalence to the gold standard. Wild-type Nissle 1917 has already demonstrated this across three decades — the engineered chassis carries that same efficacy profile into a form built for lifelong daily dosing.
Targeting JAK1 without going systemic
Combined probiotic and JAK1 large-molecule intracellular targeting, sized against a conservative benchmark.
On-site dimeric IgA production
The probiotic host colonizes the colon and releases training particles directing the immune system to produce targeted IgA that selectively binds JAK1.
Targeted dIgA selectively binds JAK1
Native pIgR escorts antibodies through epithelial membranes — allowing targeted antibodies to bind JAK1 intracellularly.
Supports intestinal healing
The Salvitus host naturally strengthens the intestinal barrier and promotes epithelial repair, the same base benefit shared by Rung 1.
DSS murine model
Multiple Salvitus assets limited DSS-induced weight loss, matching or exceeding cyclosporine A — broadly accepted as an analog for therapeutic performance. Protocol: DSS 7 days on / 7 days off, repeated; vehicle and Salvitus therapies dosed days 0–2 and day 10 onward.
Key finding
Several Salvitus assets outperformed cyclosporine A in limiting weight loss across the repeated DSS challenge.
Key note
Cyclosporine A is considered a significantly stronger therapy for UC than 5-ASA therapies — a high bar for comparison.
Rung 2 (JAK1 dIgA) asset
Key milestones from current stage to Phase I/II completion, GMO LBP autoimmune asset.
Salvitus therapeutic asset portfolio
The two lead programs preview a much larger pipeline — full breadth across all patent-pending therapeutic areas, 272 total assets.
Salvitus founders
Leadership combining scientific pioneering, legal expertise, and pharma analytics.
George Pieczenik, PhD
A foundational figure in molecular biology who co-created the first computer matrix analysis of nucleic acids with Sydney Brenner. Co-authored the landmark 1976 paper with Crick, Brenner & Klug — the only paper with three independent Nobel laureates. An early pioneer in combinatorial peptide libraries and inventor of the Salvitus therapeutic platform.
Perry Sanders, Jr., JD
A nationally recognized attorney with extensive experience in pharmaceutical safety and intellectual property. A successful entrepreneur who has founded multiple businesses and secured patents, copyrights and trademarks for strategic advantage. Has negotiated hundreds of millions of dollars in deals and served as lead or co-lead counsel in numerous noteworthy matters.
Kirk Solo, MBA
An innovator in pharmaceutical strategy and analytic forecasting whose firm has built hundreds of forecasts for most top-10 pharma companies. A published oncology author and early AI adopter who developed FDA-cleared SaMD algorithms. Trained under Dr. Pieczenik, he built the AI and computational oncology tools behind the current pipeline and carries the mantle of lead inventor.
Supporting literature
Sources for market sizing, mechanisms of action, and clinical / genotoxicity data cited across both programs.
Oncology · Market sizing & mechanisms+
Immunology · UC market, clinical & genotoxicity data+
Two de-risked programs, one oral platform, ready for a development partner.
Salvitus is seeking a development and commercialization partner to advance SALV-0251 and the engineered EcN UC platform from preclinical proof-of-concept through Phase II and beyond.